These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 27070712)

  • 21. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update.
    Tranoy-Opalinski I; Legigan T; Barat R; Clarhaut J; Thomas M; Renoux B; Papot S
    Eur J Med Chem; 2014 Mar; 74():302-13. PubMed ID: 24480360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Hypoxia: Revival of Old Remedies.
    Vilaplana-Lopera N; Besh M; Moon EJ
    Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the molecular basis for tumour hypoxia.
    Carroll VA; Ashcroft M
    Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioreductive prodrugs for cancer therapy.
    Seddon B; Kelland LR; Workman P
    Methods Mol Med; 2004; 90():515-42. PubMed ID: 14657582
    [No Abstract]   [Full Text] [Related]  

  • 26. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
    Denny WA; Wilson WR
    J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The Oxygen effect: an old new target?].
    Lartigau E; Dewas S; Gras L
    Cancer Radiother; 2008 Jan; 12(1):42-9. PubMed ID: 18261946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prodrug strategies in cancer therapy.
    Denny WA
    Eur J Med Chem; 2001; 36(7-8):577-95. PubMed ID: 11600229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The meaning, measurement and modification of hypoxia in the laboratory and the clinic.
    Hammond EM; Asselin MC; Forster D; O'Connor JP; Senra JM; Williams KJ
    Clin Oncol (R Coll Radiol); 2014 May; 26(5):277-88. PubMed ID: 24602562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.
    de Groot FM; Damen EW; Scheeren HW
    Curr Med Chem; 2001 Jul; 8(9):1093-122. PubMed ID: 11472243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
    Guise CP; Abbattista MR; Tipparaju SR; Lambie NK; Su J; Li D; Wilson WR; Dachs GU; Patterson AV
    Mol Pharmacol; 2012 Jan; 81(1):31-40. PubMed ID: 21984255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
    Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs.
    O'Connor LJ; Cazares-Körner C; Saha J; Evans CN; Stratford MR; Hammond EM; Conway SJ
    Nat Protoc; 2016 Apr; 11(4):781-94. PubMed ID: 27010756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment.
    Maslah H; Skarbek C; Pethe S; Labruère R
    Eur J Med Chem; 2020 Dec; 207():112670. PubMed ID: 32858470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxia and its therapeutic possibilities in paediatric cancers.
    Bernauer C; Man YKS; Chisholm JC; Lepicard EY; Robinson SP; Shipley JM
    Br J Cancer; 2021 Feb; 124(3):539-551. PubMed ID: 33106581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia Responsive Drug Delivery Systems in Tumor Therapy.
    Alimoradi H; Matikonda SS; Gamble AB; Giles GI; Greish K
    Curr Pharm Des; 2016; 22(19):2808-20. PubMed ID: 26898739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation.
    Govaert KM; Nijkamp MW; Emmink BL; Steller EJ; Minchinton AI; Kranenburg O; Borel Rinkes IH
    Br J Surg; 2012 Apr; 99(4):567-75. PubMed ID: 22331808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors.
    Ikeda Y; Hisano H; Nishikawa Y; Nagasaki Y
    Mol Pharm; 2016 Jul; 13(7):2283-9. PubMed ID: 27187083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of hypoxia-activated prodrugs in combination with radiation therapy: An
    Meaney C; Powathil GG; Yaromina A; Dubois LJ; Lambin P; Kohandel M
    Math Biosci Eng; 2019 Jul; 16(6):6257-6273. PubMed ID: 31698561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced nanotechnology for hypoxia-associated antitumor therapy.
    Zhao L; Fu C; Tan L; Li T; Zhong H; Meng X
    Nanoscale; 2020 Feb; 12(5):2855-2874. PubMed ID: 31965135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.